Pfizer Inc. (PFE)
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
Shares of Pfizer (PFE -2.04%) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided in October and issued guidance for the year ahead.
Pfizer Momentum Shift Makes Me Less Bullish (Technical Analysis)
Pfizer Inc.'s technical indicators have shifted from bullish to bearish, with the stock now trading below its 30-week EMA and showing bearish momentum. Volume analysis indicates recent institutional selling, and relative strength has deteriorated, underperforming the S&P 500 since July 2024. Pfizer stock is in a consolidation phase, potentially setting up for a bull run if it can recapture its 30-week EMA and show bullish volume.
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations
Pfizer projects total revenues between $61.0 and $64.0 billion with EPS in the range of $2.80 to $3.00.
Is Pfizer Stock Undervalued?
Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 billion, and its adjusted earnings to be in the range of $2.80 and $3.00 per share.
Pfizer climbs 4% on 2025 outlook
Evan David Seigerman, BMO analyst, joins 'Closing Bell Overtime' to talk Pfizer's 2025 outlook.
Pfizer's 2025 guidance positions company for EPS expansion, says BMO
BMO Capital reiterated an Outperform rating and $36 price target on Pfizer, saying that 2025 guidance succeeds in meeting the majority of the firm's expectations outlined in its preview, positioning the company for earnings per share expansion. The company's guide only just missed the firm's midpoint sales expectation, though midpoint EPS expectations of $2.90 in 2025 show roughly 2% growth year-over-year, giving investors confidence that the company has turned over a new leaf financially, the analyst tells investors in a research note. The firm continues to believe the revenue guidance is conservative, especially for ex-COVID products, leaving room for future beats and raises to sustain shares throughout the year.
Here's why Pfizer (PFE) stock is surging
Pfizer (NYSE: PFE) shares rose nearly 3% to $25.98 in premarket trading on December 17 after the pharmaceutical giant released its 2025 financial guidance.
Stock Of The Day: Is Pfizer About To Break Out? Expect A New Uptrend If Resistance Breaks
Shares of Pfizer Inc. PFE are making a large move higher Tuesday. But the stock has run into resistance.
Pfizer Inc. (PFE) Full-Year 2025 Financial Guidance Conference Call (Transcript)
Pfizer Inc. (NYSE:PFE ) Full-Year 2025 Financial Guidance Conference Call December 17, 2024 8:30 AM ET Company Participants Francesca DeMartino - Chief IRO and SVP Albert Bourla - Chairman and CEO David Denton - CFO Conference Call Participants Chris Schott - JPMorgan Geoff Meacham - Citibank Steve Scala - TD Securities Tim Anderson - Bank of America Chris Shibutani - Goldman Sachs Trung Huynh - UBS Vamil Divan - Guggenheim Evan Seigerman - BMO Capital Markets Operator Good day, everyone, and welcome to Pfizer's Analyst and Investor Call to Review Full Year 2025 Financial Guidance. Today's call is being recorded.
Pfizer Stock Rises as 2025 Outlook in Line With Expectations
Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts' estimates.
Guggenheim: Can see Pfizer reaching $10 billion in sales by 2030
Vamil Divan, Guggenheim Securities analyst, joins 'Squawk on the Street' to discuss Pfizer's guidance, how optimistic Divan is on Pfizer's product pipeline, and some of the complaints Pfizer has heard from activist investor Starboard.
2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical
Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today.
